JLJamie Linnea Luckhaus

Jamie Linnea Luckhaus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jamie Linnea Luckhaus has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Is all knowledge, good knowledge?: Multinational Patient Survey on AI-Generated Prognostic Insights and Actionability for Parkinson’s Disease (Preprint)

    by Jamie Linnea Luckhaus, Anna Kharko, Therese Scott Duncan, Charlotte Blease, David M. Lyreskog, Margherita Fabbri, Monica Kurtis, Stelios Hadjidimitriou, John Zaras, Maria Hägglund, et al.

    BACKGROUND Predictive artificial intelligence (AI) is rapidly emerging in Parkinson's disease (PD) management, yet patient perspectives remain underexplored. Actionability is a key ethical consideration in prognostic disclosure. Understanding how people with PD (PwP) value and define actionable AI-generated prognostic information is essential for patient-centered design and implementation. OBJECTIVE This study aims to examine PwP’s preferences for AI-based prognostic information and explore how actionable insights are perceived and valued. METHODS In this convergent mixed-methods study, 149 PwP completed an online survey distributed through international patient networks between April and November 2025. Quantitative data were analysed using descriptive and inferential statistics, and free-text responses underwent qualitative content analysis. RESULTS Most expressed interest in knowing their motor prognosis (71%) and milestones (74%). Nearly half (47%) would only want feedback they can act upon. There was a significant association between education level and interest in knowing which factors may influence one’s prognosis (χ²(2)=6.69, p=.04), and between time since diagnosis and only wanting actionable insights (χ²(2)=7.38, p=.02). The meaning of actionability varied between individuals, including being described as the ability to influence disease progression, facilitating preparation, and as the credibility and personal applicability of insights. For some, actionability was necessary for wanting prognostic information, while for others information was valued regardless. CONCLUSIONS Respondents valued prognostic information beyond traditional intervention-focused definitions of actionability, though substantial individual variation remained. These findings support an individualized approach to communicating prognostic information, whereby healthcare professionals regularly assess and respond to patients' evolving preferences and informational needs throughout the disease course. CLINICALTRIAL N/A

  • Open Access

    Comparing Stakeholders’ Perspectives on Parkinson Disease Management and Digital Technologies: Exploratory International Survey

    by Jamie Linnea Luckhaus, Anna Kharko, Charlotte Blease, Maria-Luisa Almarcha-Menargues, Natalia Del Campo, Sofia Balula Dias, Beatriz Alves, Björn H Falkenburger, Leontios Hadjileontiadis, Maria Hägglund, et al.

    Background: Parkinson disease (PD) is a progressive neurodegenerative disorder that poses complex challenges for persons with PD, informal caregivers, and health care professionals. With growing interest in digital and predictive artificial intelligence (AI) tools for disease management, understanding the needs and digital readiness of these stakeholder groups is crucial. Objective: This work aims to (1) identify digital practices for PD management among persons with PD, at-risk individuals, caregivers, and health care professionals; (2) compare these practices across groups; (3) explore stakeholder desires for AI-based tools; and (4) assess alignments and gaps to inform tailored AI solutions. Methods: An anonymous cross-sectional online survey of an exploratory nature was distributed (from December 2024 to October 2025) in 5 languages and completed by 255 respondents. Descriptive statistics summarized responses to 41 questions, including stakeholder-specific items. χ 2 tests were performed to examine stakeholder differences in desired AI features. Results: Interest in predictive AI was high across stakeholder groups. Symptom tracking was the most desired feature (selected by more than 76% of the respondents), and personalized treatment recommendations came second for both persons with PD and health care professionals; however, stakeholder priorities diverged in other areas. Health care professionals rated improving patient and informal caregiver engagement as significantly more important than persons with PD did, χ 2 1 (n=205)=34.78, P <.001, and Cramer V=0.41. Despite considerable interest, the reported use of digital tools was limited, as most persons with PD did not use symptom-tracking apps or wearables, nor were they currently monitoring their condition, although many expressed intentions to begin. Conclusions: While predictive AI tools were viewed positively across groups, there were significant gaps in stakeholder preferences, highlighting the importance of tailored, context-aware design. Early diagnosis was not prioritized by persons with PD or health care professionals, likely reflecting the complexity of diagnosing PD in the absence of disease-modifying therapies. Coupled with the emphasis placed on preventive lifestyle guidance by persons with PD and those at risk, this highlights the importance of actionability in AI-based monitoring and prediction. Such actionability may also enhance perceived relevance and uptake, given that reported interest in digital health tools and self-tracking exceeded actual use. These findings offer early-stage insight to guide the development of future AI-based solutions for PD.

  • Open Access

    “ChatGPT knows my Parkinson's”: Perspectives of people with Parkinson's disease on use of generative AI

    by Jamie Linnea Luckhaus, Anna Kharko, Therese Scott Duncan, Sara Riggare, Maria Hägglund, Charlotte Blease

    Patients’ use of generative AI (GenAI) independently from healthcare is increasing across diseases. Little is known about its use among people with Parkinson's disease (PwP). This exploratory convenience-sample, mixed-methods online survey (n = 149, 19 countries) explored PwP's use of GenAI. Among our respondents, 65% had used GenAI, of which 40% had used it for disease-specific inquiries. Qualitative analysis identified informational, interpretive, and preparational uses of GenAI. As PwP increasingly bring AI-assisted data to consultations, clinicians must now actively engage in discussions about these tools, to support shared decision-making, safety and transparency.


  • Open Access

    Comparing Stakeholders’ Perspectives on Parkinson’s Disease Management and Digital Technologies: An Exploratory International Survey (Preprint)

    by Jamie Linnea Luckhaus, Anna Kharko, Charlotte Blease, Maria-Luisa Almarcha-Menargues, Natalia Del Campo, Sofia Balula Dias, Beatriz Alves, Björn H Falkenburger, Leontios Hadjileontiadis, Maria Hägglund, et al.

    BACKGROUND Parkinson’s disease (PD) is a progressive neurodegenerative disorder that poses complex challenges for persons with Parkinson’s (PwP), informal caregivers, and healthcare professionals. With growing interest in digital and predictive Artificial Intelligence (AI) tools for disease management, understanding the needs and digital readiness of these stakeholder groups is crucial. OBJECTIVE This work aims to (1) identify digital practices for PD management among PwP, at‑risk individuals, caregivers, and healthcare professionals; (2) compare these practices across groups; (3) explore stakeholder desires for AI-based tools; and (4) assess alignments and gaps to inform tailored AI solutions. METHODS An anonymous cross-sectional online survey of exploratory nature was distributed (from Dec. 2024 to Oct. 2025) in five languages. It was completed by 255 respondents. Descriptive statistics summarized responses to 41 questions, including stakeholder-specific items. Chi-square tests were performed to examine stakeholder differences in desired AI-features. RESULTS : Interest in predictive AI was high across stakeholder groups. Symptom-tracking was the most desired feature (selected by >76% of respondents); however, stakeholder priorities diverged in other areas. Healthcare professionals rated improving patient and informal caregiver engagement as significantly more important than PwP did, χ²(1, N=205)=34.78, p<.001, Cramer’s V=0.41. Despite considerable interest, the reported use of digital tools was limited, as most PwP did not use symptom-tracking apps or wearables, nor were they currently monitoring their condition, although many expressed intentions to begin. CONCLUSIONS While AI tools were viewed positively across groups, there were significant gaps in current usage. Stakeholder-specific preferences, including informal caregiver engagement and preventive lifestyle guidance, highlight the importance of tailored design. These findings offer early-stage insight to guide development of future AI-based solutions for PD.

  • Open Access

    Co-Designing a “win-win” in Predictive AI: First Results from Interviews and Focus Groups with Persons with Parkinson’s Disease

    by Jamie Luckhaus, Sara Riggare, Anna Kharko, Charlotte Blease, Maria Hägglund, Therese Scott Duncan

    This study explored the perspectives of people with Parkinson’s disease (PwP) involved in the co-design of AI tools for PD care. The aim was to understand PwP perspectives on AI tools and identify factors influencing their engagement. A qualitative triangulation of 13 interviews and two focus groups were conducted with a panel of 14 PwPs from six European countries. Data analysis employed inductive content analysis which resulted in 3 categories. Patients emphasized the potential of AI tools to increase patient agency and improve healthcare through co-design. While AI-based medication response prediction was highly regarded, risk assessment tools were met with skepticism. Participants stressed the importance of taking into account disease complexity, individual factors, data protection, and transparency in AI model development. Participants strongly believed in the co-design process, and the value that it could bring to all parties involved in the development of the AI-based tools, ensuring the development of tools that are beneficial and trustworthy.

  • Open Access

    Balancing Hope and Harm: A Qualitative Exploration of Ethical Aspects of using AI in Parkinson’s Disease (Preprint)

    by Jamie Linnea Luckhaus, Therese Scott Duncan, Anna Kharko, Anna Clareborn, Maria Hägglund, Charlotte Blease, Sara Riggare

    As Parkinson disease (PD) rates increase, so does interest in finding new technological solutions for PD management. Despite substantial efforts to explore potential applications of artificial intelligence (AI) in PD management, research from the perspectives of people with PD on AI remains limited. This study aims to explore the ethical considerations of AI in PD management from the perspective of people with PD. A qualitative triangulation of 13 interviews and 2 focus groups (FGs) with a panel of expert-by-experience people with PD from 6 European countries was carried out using abductive thematic analysis. The 6 biomedical ethical principles conceptualized by Beauchamp and Childress guided the analysis. Participants varied in diagnosis, disease experiences, and technological backgrounds. A researcher with PD was involved from start to finish, providing valuable insights into data collection and analysis. Although optimistic that AI could enhance autonomy and beneficence through personalized, actionable insights for people with PD and their health care professionals, concerns arose over patient involvement, model accuracy and privacy, ethical injustices, and the psychological impact. Risk prediction, prognosis, and medication response were viewed differently in terms of potential value and ethical considerations, with risk prediction being perceived as the most ethically complex. To uphold autonomy, it was considered important for AI insights to be patient-accessible, and sensitive insights should be communicated by a health care professional who recognizes individual differences in desiring and responding to AI predictions. While people with PD felt AI could personalize (self-)care and increase autonomy, concerns about psychological harm and widening inequalities highlight the importance of ethical safeguards. Our findings underscore the importance of AI integrations that prioritize individual needs, actively engage people with PD in the development, implementation, and interpretation of predictive AI, and establish guidelines to support health care professionals and minimize patient harm. Different forms of implementation and precautions should be taken for risk, progression, and medication response prediction.


  • Open Access

    Balancing Hope and Harm: A Qualitative Exploration of Ethical Aspects of using AI in Parkinson’s Disease (Preprint)

    by Jamie Linnea Luckhaus, Therese Scott Duncan, Anna Kharko, Anna Clareborn, Maria Hägglund, Charlotte Blease, Sara Riggare

    BACKGROUND As Parkinson’s disease (PD) rates increase, so does interest in finding new technological solutions for PD management. Despite substantial efforts to explore potential applications of AI in PD management, research from people with PD (PwP)’s perspectives on AI remains limited. OBJECTIVE To explore ethical considerations of AI in PD management from a PwP perspective. METHODS A qualitative triangulation of 13 interviews and two focus groups with an expert panel of PwP from six European countries was carried out using abductive thematic analysis. The six biomedical ethical principles conceptualized by Beauchamp and Childress guided the analysis. Participants varied in diagnosis, disease experiences and technological backgrounds. A researcher with PD was involved from start to finish, providing valuable insights to data collection and analysis. RESULTS While optimistic that AI could enhance autonomy and beneficence through personalized, actionable insights for PwP and their healthcare professionals, concerns arose over patient involvement, model accuracy and privacy, ethical injustices, and the psychological impact. Risk prediction, prognosis, and medication response were viewed differently in terms of potential value and ethical considerations, with risk prediction being perceived as the most ethically complex. To uphold autonomy, it was considered important for AI insights to be patient-accessible, and that sensitive insights should be communicated by a healthcare professional who recognizes individual differences in desiring and responding to AI predictions. CONCLUSIONS While PwP felt AI could personalize (self-)care and increase autonomy, concerns of psychological harm and widening inequalities highlight the importance of ethical safeguards. Our findings underscore the importance of AI integrations that prioritize individual needs, actively involving PwP in the development, implementation, and interpretation of predictive AI, and guidelines to assist healthcare professionals and avoid patient harm. Different forms of implementation and precautions should be taken for risk, progression, and medication response prediction.


  • Open Access

    Impact of healthcare education on preferences for electronic health records: Results from national survey of patient users in Sweden

    by Anna Kharko, Jamie Linnea Luckhaus, Charlotte Blease, Åsa Cajander, Josefin Hagström, Bridget T Kane, Gunnar O Klein, Sari Kujala, Jonas Moll, Isabella Scandurra, et al.

    Electronic health records (EHR) are continuously evolving to better meet user needs, but the process is complicated by healthcare professionals and patients often disagreeing on priority areas of development. While this may be due to differences between professional and personal experiences, little is known whether specialist healthcare knowledge also affects user needs when using EHRs as patients. To investigate this, we analysed the responses of patient users in Sweden from the NORDeHEALTH 2022 Patient Survey. In the survey, respondents indicated whether they had healthcare education, and rated how useful various EHR information types and functions are. Average ratings were comparable between the two user groups, but significant differences were observed for information types and functions. Those without healthcare education rated the ability to point out errors as most useful, while those with healthcare education — the ability to contribute health information. The findings suggest healthcare education can influence users’ EHR preferences.


  • Open Access

    Understanding Co‐Creation in a Research Partnership Programme Exploring Patient‐Driven Innovations: A Qualitative Longitudinal Study

    by Hanna Jansson, Jamie L. Luckhaus, Henna Hasson, Pamela Mazzocato, Terese Stenfors, Carolina Wannheden

    Background: Research indicates that successful co‐creation depends on a shared understanding of co‐creation and its related concepts. However, it also shows that, in practice, views on co‐creation and how to do it differ. This study aims to explore how patient innovators and researchers in a partnership research programme understand co‐creation and how this understanding changes over time.Methods: An explorative longitudinal qualitative study was conducted with the ‘Patients in the Driver's Seat’ partnership research programme. Fifty‐eight interviews were performed and analysed using a reflexive thematic approach.Findings: Four different ways of understanding co‐creation were identified. These can be instrumentally conceptualized as themes using the inputs‐process‐outputs model: (1) combining different perspectives, experiences and backgrounds (inputs); (2) deliberately dynamic and exploratory (process); (3) striving for equity, not equality (process); and (4) diverse value creation, tangible and intangible (outputs). Together, these themes represent the varied understandings of co‐creation among partnership programme members.Conclusions: Our study of patient innovators and researchers identified four distinct yet complementary understandings of co‐creation. The study suggests that co‐creation is the sum of its essential components, which can be divided into inputs, process, and outputs.Patient or Public Contribution: This study, and the partnership programme it explored, aims to improve the relevance of research for patients and informal caregivers through an improved understanding of the concept of co‐creation within research on patient innovation. All patient innovators involved in the programme were invited, as interviewees and researchers, to contribute to the study design and data analysis.

  • Open Access

    A Patient-Driven Mobile Health Innovation in Cystic Fibrosis Care: Comparative Cross-Case Study

    by Pamela Mazzocato, Jamie Linnea Luckhaus, Moa Malmqvist Castillo, Johan Burnett, Andreas Hager, Gabriela Oates, Carolina Wannheden, Carl Savage

    Background: Patient-driven innovation in health care is an emerging phenomenon with benefits for patients with chronic conditions, such as cystic fibrosis (CF). However, previous research has not examined what may facilitate or hinder the implementation of such innovations from the provider perspective. Objective: The aim of this study was to explain variations in the adoption of a patient-driven innovation among CF clinics. Methods: A comparative multiple-case study was conducted on the adoption of a patient-controlled app to support self-management and collaboration with health care professionals (HCPs). Data collection and analysis were guided by the nonadoption, abandonment, spread, scale-up, and sustainability and complexity assessment tool (NASSS-CAT) framework. Data included user activity levels of patients and qualitative interviews with staff at 9 clinics (n=8, 88.9%, in Sweden; n=1, 11.1%, in the United States). We calculated the maximum and mean percentage of active users at each clinic and performed statistical process control (SPC) analysis to explore how the user activity level changed over time. Qualitative data were subjected to content analysis and complexity analysis and used to generate process maps. All data were then triangulated in a cross-case analysis. Results: We found no evidence of nonadoption or clear abandonment of the app. Distinct patterns of innovation adoption were discernable based on the maximum end-user activity for each clinic, which we labeled as low (16%-23%), middle (25%-47%), or high (58%-95%) adoption. SPC charts illustrated that the introduction of new app features and research-related activity had a positive influence on user activity levels. Variation in adoption was associated with providers’ perceptions of care process complexity. A higher perceived complexity of the value proposition, adopter system, and organization was associated with lower adoption. In clinics that adopted the innovation early or those that relied on champions, user activity tended to plateau or decline, suggesting a negative impact on sustainability. Conclusions: For patient-driven innovations to be adopted and sustained in health care, understanding patient-provider interdependency and providers’ perspectives on what generates value is essential.